Endocrinology
The American Diabetes Association (ADA) has launched its Corporate Health Ambassador initiative, recognizing companies that demonstrate a commitment to helping employees lead healthier lifestyles. The initiative aims to combat the rising rates of type 2 diabetes in America, which is largely attributable to poor diet and physical inactivity. Companies such
Endocrinology
The American Diabetes Association (ADA) has initiated a program to recognize companies that promote healthy lifestyles among their employees, aiming to combat the growing issue of type 2 diabetes. As part of this initiative, several major corporations have pledged to support employee health and wellness programs, leveraging the workplace as
Endocrinology
A recent issue of Diabetologia highlights the severity of diabetic foot ulceration, which affects millions of people globally. According to expert Andrew J. M. Boulton, over 5% of diabetic patients have a history of foot ulceration, with a cumulative lifetime incidence of up to 15%. The study also reveals ethnic
Endocrinology
Researchers at Vitro Diagnostics, Inc. have made a significant breakthrough in the development of human pancreatic beta islets, which could potentially treat type I diabetes. The company has developed an in vitro model system of human stem cells that can be induced to form beta islets under specific environmental conditions.
Endocrinology
NeuroMetrix, Inc. has made an important advance in the management of diabetic peripheral neuropathy (DPN), a condition that affects over 18 million Americans. According to the American Diabetes Association, over half of diabetes patients have DPN, and as many as three-quarters are unaware of their nerve degeneration until symptoms appear.
Endocrinology
Diabetic peripheral neuropathy, a painful and often debilitating condition affecting over 18 million Americans, has long been a challenge for healthcare professionals. The recent U.S. Food and Drug Administration (FDA) priority approval of Cymbalta (duloxetine HCl) for managing pain caused by diabetic nerve damage marks a significant milestone in
Endocrinology
Researchers at Antigen Express, a subsidiary of Generex Biotechnology Corp., have made significant progress in developing a diagnostic kit to identify individuals in the earliest stage of type 1 diabetes mellitus. By studying novel hybrid peptides, which include antigenic epitopes that trigger diabetes, scientists have discovered that these peptides can
Endocrinology
Pancreatic beta-cell survival and function play a crucial role in glucose homeostasis and diabetes management. A recent study by Navarro-Tableros and colleagues at the Universidad Nacional Autonoma de Mexico has shed light on the autocrine regulation of insulin and nerve growth factor (NGF) on single adult rat pancreatic beta-cell survival
Endocrinology
Researchers have conducted a thorough review of wound dressings for diabetic foot disease, highlighting the importance of dressing choice in managing infected foot ulcers. The study, published in Clinical Infectious Diseases, emphasizes that no single dressing satisfies all the requirements of a diabetic patient with an infected foot ulcer. Various
Endocrinology
The U.S. Food and Drug Administration (FDA) has given its approval to Cymbalta (duloxetine HCl), a groundbreaking antidepressant that can effectively manage diabetic peripheral neuropathic pain, a symptom of nerve damage that affects up to 5 million Americans. Cymbalta, a serotonin and norepinephrine reuptake inhibitor, is the first and
Diabetes mellitus
Insmed, a biopharmaceutical company, has announced the initiation of a phase I clinical study for its novel anti-tumor agent, recombinant human Insulin-Like Growth Factor Binding Protein-3 (rhIGFBP-3). The study aims to evaluate the safety, tolerability, and pharmacokinetics of a single intravenous dose of rhIGFBP-3 in 30 patients. The primary goal
Diabetes mellitus
Researchers at the Aichi Cancer Center in Japan conducted a meta-analysis to investigate the association between circulating insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3, and the risk of premenopausal breast cancer. The study, published in the International Journal of Cancer, analyzed data from seven nested case-control and population-based
